Role of interleukin-23/interleukin-17 axis in T-cell-mediated actions in hypertension

Cardiovasc Res. 2021 Apr 23;117(5):1274-1283. doi: 10.1093/cvr/cvaa257.

Abstract

Current knowledge suggests that hypertension is in part mediated by immune mechanisms. Both interleukin (IL)-23 and IL-17 are up-regulated in several experimental hypertensive rodent models, as well as in hypertensive humans in observational studies. Recent preclinical studies have shown that either IL-23 or IL-17A treatment induce blood pressure elevation. However, the IL-23/IL-17 axis has not been a major therapeutic target in hypertension, unlike in other autoimmune diseases. In this review, we summarize current knowledge on the role of these cytokines in immune mechanisms contributing to hypertension, and discuss the potential of IL-23/IL-17-targeted therapy for treatment of hypertension.

Keywords: Adaptive immunity; Immune therapy; Interleukin-23 receptor.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Anti-Inflammatory Agents / therapeutic use
  • Antihypertensive Agents / therapeutic use
  • Blood Pressure* / drug effects
  • Humans
  • Hypertension / drug therapy
  • Hypertension / immunology
  • Hypertension / metabolism*
  • Hypertension / physiopathology
  • Immunity, Cellular* / drug effects
  • Inflammation Mediators / antagonists & inhibitors
  • Inflammation Mediators / metabolism*
  • Interleukin-17 / antagonists & inhibitors
  • Interleukin-17 / metabolism*
  • Interleukin-23 / antagonists & inhibitors
  • Interleukin-23 / metabolism*
  • Molecular Targeted Therapy
  • Receptors, Interleukin / metabolism
  • Signal Transduction
  • T-Lymphocytes / drug effects
  • T-Lymphocytes / immunology
  • T-Lymphocytes / metabolism*

Substances

  • Anti-Inflammatory Agents
  • Antihypertensive Agents
  • IL23R protein, human
  • Inflammation Mediators
  • Interleukin-17
  • Interleukin-23
  • Receptors, Interleukin

Grants and funding